M-CERSI is interested in better understanding how clinicians currently use, and have historically used, certain bulk drug substances nominated for use in compounding by outsourcing facilities under section 503B of the Federal Food, Drug, and Cosmetic Act.

We want to understand how medical practitioners prescribe and administer compounded drugs. Your feedback will help the Food and Drug Administration (FDA) develop a list of drugs that can be used in bulk compounding by 503B outsourcing facilities. Your anonymous responses will be shared with the FDA as part our of our project, "Clinical Use of Drugs Including Bulk Drug Substances Nominated for Use in Compounding by Outsourcing Facilities."

The time required to complete this survey is approximately 10-15 minutes.

If you would like to tell us more about your use of compounded products, contact us at compounding@rx.umaryland.edu. Thank you for your participation.

Please note that substances are listed by specialty. Click or tap on the categories below to expand each list and see the individual links for all of the substances being surveyed.

Allergy and Immunology

Anesthesiology

Cardiology

Dentistry and Oral Medicine

Dermatology

Emergency Medicine and Critical Care

Endocrinology

Gastroenterology

Hematology

Hepatology

Infectious Disease

Naturopathy

Nephrology

Neurology

Nutrition

Obstetrics and Gynecology

Oncology

Ophthalmology

Orthopedics and Osteopathic Medicine

Otolaryngology

Pain Management

Palliative Care

Pediatrics and Neonatology

Primary Care and Internal Medicine

Proctology

Psychiatry

Rheumatology

Surgery

Toxicology

Urology